Form 4: Verona Pharma Director Kenneth Cunningham Awarded 96,000 Restricted Share Units

Director Kenneth Cunningham receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.

Summary

• Kenneth Cunningham, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025.
• Each RSU represents the right to receive one American Depositary Share (ADS), and each ADS represents eight ordinary shares of Verona Pharma.
• The RSUs will vest in four equal installments of 25% each, on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026, contingent upon Cunningham's continued service to the company.
• The reporting person's attorney-in-fact, Andrew Fisher, signed the Form 4 on April 29, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice that aligns management and shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the RSUs is dependent on the future performance of Verona Pharma's stock price.
• If Cunningham ceases to be a director before the vesting dates, the unvested RSUs will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Granting RSUs to directors is a common practice in publicly traded companies to align management's interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability to increase the value of the RSUs.

Key Dates

Keywords

Verona Pharma, Kenneth Cunningham, Restricted Share Units, RSU, Director, Vesting, ADS, Ordinary Shares, Form 4